Although BTK and CD79A were downregulated in overall PT-DLBCL compared with systemic DLBCL (therefore in the systemic DLBCL signature, Fig. 2A), the downregulation was mainly in the ME (Fig. 2F) and wild-type MYD88 subsets (Supplementary Fig. 4A). Here, MYD88 is linked to diffuse large B-cell lymphoma.